Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) EVP Jennifer Kayden Lee Sells 1,815 Shares

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM - Get Free Report) EVP Jennifer Kayden Lee sold 1,815 shares of Rhythm Pharmaceuticals stock in a transaction that occurred on Wednesday, February 12th. The stock was sold at an average price of $56.39, for a total value of $102,347.85. Following the transaction, the executive vice president now owns 3,598 shares in the company, valued at approximately $202,891.22. The trade was a 33.53 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Jennifer Kayden Lee also recently made the following trade(s):

• On Monday, February 10th, Jennifer Kayden Lee sold 4,189 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $58.91, for a total value of $246,773.99.
• On Tuesday, February 4th, Jennifer Kayden Lee sold 1,447 shares of Rhythm Pharmaceuticals stock. The stock was sold at an average price of $59.43, for a total value of $85,995.21.

Rhythm Pharmaceuticals Price Performance

Shares of RYTM stock traded up $0.09 on Tuesday, hitting $56.78. The stock had a trading volume of 117,478 shares, compared to its average volume of 464,099. The firm has a market capitalization of $3.49 billion, a P/E ratio of -13.10 and a beta of 2.14. Rhythm Pharmaceuticals, Inc. has a 1 year low of $35.17 and a 1 year high of $68.58. The company's 50 day moving average price is $57.05 and its 200-day moving average price is $53.74.

Institutional Investors Weigh In On Rhythm Pharmaceuticals

Institutional investors and hedge funds have recently modified their holdings of the company. Loomis Sayles & Co. L P acquired a new position in Rhythm Pharmaceuticals during the 3rd quarter worth $33,353,000. Janus Henderson Group PLC grew its stake in Rhythm Pharmaceuticals by 103.9% during the 4th quarter. Janus Henderson Group PLC now owns 1,219,554 shares of the company's stock worth $68,309,000 after purchasing an additional 621,432 shares in the last quarter. Marshall Wace LLP grew its stake in Rhythm Pharmaceuticals by 70.4% during the 4th quarter. Marshall Wace LLP now owns 692,803 shares of the company's stock worth $38,783,000 after purchasing an additional 286,188 shares in the last quarter. Norges Bank acquired a new position in Rhythm Pharmaceuticals during the 4th quarter worth $11,512,000. Finally, JPMorgan Chase & Co. grew its stake in Rhythm Pharmaceuticals by 224.3% during the 4th quarter. JPMorgan Chase & Co. now owns 264,585 shares of the company's stock worth $14,811,000 after purchasing an additional 182,993 shares in the last quarter.

Analysts Set New Price Targets

RYTM has been the topic of a number of analyst reports. JMP Securities reiterated a "market outperform" rating and set a $75.00 price objective on shares of Rhythm Pharmaceuticals in a research report on Monday, December 23rd. Needham & Company LLC lifted their target price on Rhythm Pharmaceuticals from $55.00 to $64.00 and gave the company a "buy" rating in a research report on Wednesday, November 6th. The Goldman Sachs Group lifted their target price on Rhythm Pharmaceuticals from $59.00 to $66.00 and gave the company a "buy" rating in a research report on Thursday, December 5th. Canaccord Genuity Group restated a "buy" rating and issued a $80.00 target price on shares of Rhythm Pharmaceuticals in a research report on Tuesday, November 19th. Finally, Guggenheim initiated coverage on Rhythm Pharmaceuticals in a research report on Monday, October 21st. They issued a "buy" rating and a $70.00 target price on the stock. One equities research analyst has rated the stock with a hold rating and ten have assigned a buy rating to the company. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $68.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome.